Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.70 |
| ▸ | FAP | Q12884 | 1/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Anhydrous SCHEMBL18894359 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL29355255 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL2040329 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL497725 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6FAPFGFR1SLC22A6 | |
| Tenofovir Anhydrous SCHEMBL18492311 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL20295138 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL19586794 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL3133933 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL400718 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP | |
| Tenofovir Anhydrous SCHEMBL22206868 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 36069 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746907-A1 | METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE | Gilead Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122070288-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122036801-A | Crystalline forms of tenofovir alafenamide | 吉利德科学公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | claimed |
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| WO-2002033402-A2 | ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY | VIRCO BVBA (BE) | 2002-04-25 | — | — | WO | claimed |
| WO-2002000613-A2 | INHIBITORS OF HEPATITIS B VIRUS INFECTION | AXXIMA PHARMACEUTICALS AG (DE) | 2002-01-03 | — | — | WO | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| WO-2001047511-A2 | TREATMENT OF DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-07-05 | — | — | WO | claimed |
| WO-2001039724-A2 | PHOSPHONATE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2001-06-07 | — | — | WO | claimed |
| US-6194391-B1 | CS-87 (TITLE COMPOUND) INDUCES A TRANSIENT MUTATION IN HIV-1 AT THE 70TH CODON OF THE REVERSE TRANSCRIPTASE REGION OF THE VIRUS; ADMINISTERING TO A HUMAN IN NEED OF THERAPY WITH A DRUG THAT INDUCES A MUTATION IN HIV-1 AT ANOTHER LOCATION | EMORY UNIVERSITY | 2001-02-27 | — | — | US | claimed |
| US-6057305-A | Antiretroviral enantiomeric nucleotide analogs | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2000-05-02 | — | — | US | claimed |
| EP-0654037-B1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 1999-05-12 | — | — | EP | claimed |
| EP-0654037-A1 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1995-05-24 | — | — | EP | claimed |
| WO-1994003467-A2 | ANTIRETROVIRAL ENANTIOMERIC NUCLEOTIDE ANALOGS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1994-02-17 | — | — | WO | claimed |